NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
AstraZeneca
National Cancer Institute (NCI)
Eisai Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Bristol-Myers Squibb
AstraZeneca